Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review.

16 , 24 , 30 , 34 , 47 One study demonstrated that in patients with T2DM, orlistat in combination with participation in a clinical weight‐loss program resulted in a numerically better weight‐loss response compared with orlistat alone, although the difference failed to reach statistical significance (Table 3 ). 34 In another study, no differences were reported in weight loss between patients with or without T2DM treated with phentermine, PHEN/TPM, or liraglutide, but a difference was demonstrated with NTX/BPN (T2DM, −4.8 kg vs. non‐T2DM, −2.2 kg; p = 0.05; Table 3 ) although patient number

also in 6,035 other papers

However, small increases in HR from baseline were reported in phentermine‐treated patients, although this did not reach statistical significance. 36 , 40 Two studies reported on the effect of PHEN/TPM on cardiometabolic risk factors, with few changes in blood pressure, lipids, or glycemia observed (Table 5 ). 33 , 42 3.3.3 Liraglutide Few data ( n = 2 studies) were identified regarding the impact of liraglutide on cardiometabolic risk factors (Table 5 ).

also in 111,027 other papers